Literature DB >> 34084593

Pathogens and drug-resistance of hospital-acquired pneumonia in an EICU in Tianjin, China.

Yanan Zhang1, Songtao Shou2.   

Abstract

OBJECTIVE: Observing the pathogens and drug-resistance within hospital-acquired pneumonia (HAP) in an emergency intensive care unit (EICU) to provide a reference for clinically reasonable use of antibiotics.
METHODS: Sixty-two patients with HAP in Tianjin Medical University General Hospital from January 2017 to May 2019 were analyzed retrospectively. Bacterial identification and susceptibility were reviewed.
RESULTS: One hundred and thirty-seven strains of pathogenic bacteria were isolated from 62 patients, with 97.1% Gram-negative and only 2.9% Gram-positive. There were also six fungal isolates. The most common pathogens were Acinetobacter baumannii, accounting for 30.8% of all isolates, followed by Klebisella spp, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Escherichia coli. Acinetobacter baumannii was poorly susceptible to piperacillin-tazobactam, cefepime, Amoxicillin+clavulonic acid, ciprofloxacin. However, the isolates were sensitive to Tigecycline, so as the isolates of Klebisella spp. Pseudomonas aeruginosa was mostly sensitive to Amikacin, followed by Tobramycin. All of the isolates of Staphylococcus aureus were susceptible to Linezolid, Tigecycline and Vancomycin.
CONCLUSIONS: Gram-negative bacteria especially Acinetobacter baumannii, are the main pathogens for HAP in the observed EICU. The variety of pathogens should be monitored at regular intervals to improve resistance issues and therapeutic effect. IJBMB
Copyright © 2021.

Entities:  

Keywords:  EICU; Hospital-acquired pneumonia; drug resistance; pathogens

Year:  2021        PMID: 34084593      PMCID: PMC8166653     

Source DB:  PubMed          Journal:  Int J Biochem Mol Biol        ISSN: 2152-4114


  18 in total

1.  The utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: A multicentre, prospective study.

Authors:  Akihiro Ito; Isao Ito; Daiki Inoue; Satoshi Marumo; Tetsuya Ueda; Hiroaki Nakagawa; Masato Taki; Atsushi Nakagawa; Shuji Tatsumi; Takashi Nishimura; Tetsuhiro Shiota; Tadashi Ishida
Journal:  Int J Infect Dis       Date:  2020-01-22       Impact factor: 3.623

2.  Incidence and costs of ventilator-associated pneumonia in the adult intensive care unit of a tertiary referral hospital in Mexico.

Authors:  Oscar Sosa-Hernández; Bernadine Matías-Téllez; Abril Estrada-Hernández; Monica Alethia Cureño-Díaz; Juan Manuel Bello-López
Journal:  Am J Infect Control       Date:  2019-04-11       Impact factor: 2.918

Review 3.  Prevention of hospital-acquired pneumonia.

Authors:  Patrick G Lyons; Marin H Kollef
Journal:  Curr Opin Crit Care       Date:  2018-10       Impact factor: 3.687

4.  High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia.

Authors:  Doo Ryeon Chung; Jae-Hoon Song; So Hyun Kim; Visanu Thamlikitkul; Shao-Guang Huang; Hui Wang; Thomas Man-Kit So; Rohani M D Yasin; Po-Ren Hsueh; Celia C Carlos; Li Yang Hsu; Latre Buntaran; M K Lalitha; Min Ja Kim; Jun Yong Choi; Sang Il Kim; Kwan Soo Ko; Cheol-In Kang; Kyong Ran Peck
Journal:  Am J Respir Crit Care Med       Date:  2011-09-15       Impact factor: 21.405

5.  High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial.

Authors:  Astrid Pérez; Eva Gato; José Pérez-Llarena; Felipe Fernández-Cuenca; María José Gude; Marina Oviaño; María Eugenia Pachón; José Garnacho; Verónica González; Álvaro Pascual; José Miguel Cisneros; Germán Bou
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

6.  Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance.

Authors:  Laia Fernández-Barat; Miquel Ferrer; Francesca De Rosa; Albert Gabarrús; Mariano Esperatti; Silvia Terraneo; Mariano Rinaudo; Gianluigi Li Bassi; Antoni Torres
Journal:  J Infect       Date:  2016-11-16       Impact factor: 6.072

Review 7.  Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia.

Authors:  Charles-Edouard Luyt; Guillaume Hékimian; Despoina Koulenti; Jean Chastre
Journal:  Curr Opin Crit Care       Date:  2018-10       Impact factor: 3.687

8.  [Adult hospital acquired pneumonia: a multicenter study on microbiology and clinical characteristics of patients from 9 Chinese cities].

Authors:  You-ning Liu; Bin Cao; Hui Wang; Liang-an Chen; Dan-yang She; Tie-mei Zhao; Zhi-xin Liang; Tie-ying Sun; Yan-ming Li; Zhao-hui Tong; Zhen Wang; Bei He; Wei Yang; Jie-ming Qu; Xiang-yang Li; Rong-chang Chen; Feng Ye; Jian Kang; Er-ran Li; Ping Chen; Yan Zheng; Zhong-sen Ma; Jin Ren; Yi Shi; Wen-kui Sun; Yu-lin Feng; Hong Fan; Shu-juan Jiang; Song Zhang; Sheng-dao Xiong; Peng Zuo; Zhan-wei Wang
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2012-10

Review 9.  The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A systematic review and meta-analysis.

Authors:  S Mohd Sazlly Lim; A Zainal Abidin; S M Liew; J A Roberts; F B Sime
Journal:  J Infect       Date:  2019-09-30       Impact factor: 6.072

10.  Ventilator-Associated Pneumonia due to Drug-Resistant Acinetobacter baumannii: Risk Factors and Mortality Relation with Resistance Profiles, and Independent Predictors of In-Hospital Mortality.

Authors:  Aušra Čiginskienė; Asta Dambrauskienė; Jordi Rello; Dalia Adukauskienė
Journal:  Medicina (Kaunas)       Date:  2019-02-13       Impact factor: 2.430

View more
  1 in total

1.  Differentiation Between Acinetobacter Baumannii Colonization and Infection and the Clinical Outcome Prediction by Infection in Lower Respiratory Tract.

Authors:  Ding-Yun Feng; Jian-Xia Zhou; Xia Li; Wen-Bin Wu; Yu-Qi Zhou; Tian-Tuo Zhang
Journal:  Infect Drug Resist       Date:  2022-09-12       Impact factor: 4.177

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.